Risdiplam Gets Prority Review for Presymptomatic Spinal Muscular Atrophy
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for risdiplam for use in presymptomatic infants less than 2 months of age with spinal muscular atrophy (SMA).…